In a report released yesterday, Kaveri Pohlman from BTIG maintained a Buy rating on NexImmune (NEXI – Research Report), with a price target of $5.00. The company’s shares closed yesterday at $1.26.
According to TipRanks, Pohlman is an analyst with an average return of -10.2% and a 27.45% success rate. Pohlman covers the Healthcare sector, focusing on stocks such as MacroGenics, Nuvation Bio, and NexImmune.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for NexImmune with a $4.50 average price target.
See the top stocks recommended by analysts >>
NEXI market cap is currently $28.78M and has a P/E ratio of -0.50.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NEXI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ body’s T cells to generate immune response that mimics natural biology. Its creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases.
Read More on NEXI:
- BTIG Reaffirms Their Buy Rating on Wheels Up Experience (UP)
- BTIG Remains a Buy on Poseida Therapeutics (PSTX)
- Analysts Are Neutral on Top Utilities Stocks: Northwestern (NWE), South Jersey Industries (SJI)
- Analysts Are Bullish on These Consumer Goods Stocks: Mercadolibre (MELI), US Foods Holding (USFD)
- Analysts Conflicted on These Industrial Goods Names: Littelfuse (LFUS), The Middleby (MIDD) and ESS Tech (GWH)
